Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
AMGN Analyst Ratings
Moderate Buy
11 Buy
7 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AMGN Stock 12 Month Forecast
Average Price Target
$328.75
▲(11.72% Upside)
| Highest Price Target$389.00 | Average Price Target$328.75 | Lowest Price Target$275.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bernstein
Reiterated
02/20/25
Citi
Reiterated
02/13/25
Piper Sandler
Reiterated
02/10/25
Bank of America Securities
Reiterated
02/06/25
Leerink Partners
Reiterated
02/05/25
Morgan Stanley
Reiterated
02/05/25
Erste Group
Upgraded
02/05/25
Truist Financial
Reiterated
02/05/25
Cantor Fitzgerald
Reiterated
02/05/25
RBC Capital
Reiterated
02/04/25
TD Cowen
$383→$389
Buy
32.19%
Upside
Reiterated
02/04/25
Amgen's Strong Financial Performance and Promising Pipeline Underpin Buy Rating2:23 AM AMGEN (NASDAQ: AMGN) Buy (1) ESG $389.00 (Prior $383.00) SOLID Q4 TEES UP ANOTHER CATALYST-RICH YEAR AHEAD: NEW PT $389 (+$6) THE TD COWEN INSIGHT Q4 revs/EPS beat driven by solid Amjevita, Repatha, Blincyto, & Krystexxa sales. MariTide entering Ph3 in H1 + full Ph2 obesity data at ADA in June followed by part 2 data & Ph2 T2D data in H2:25. Next obesity candidate AMG 513 on clinical hold in Ph1, but mgmt confident in resolution. Uplizna 4/3/25 PDUFA in IgG4-RD + gMG filing in H1. Add'l roca Ph3 AD data + bema Ph3 data also slated for 2025.
Wells Fargo
$280
Hold
-4.85%
Downside
Reiterated
02/04/25
Amgen's Hold Rating: Balancing Innovative Growth and Performance Uncertainties
Mizuho Securities
―
Hold
―
Reiterated
02/04/25
Cautious Outlook on Amgen Amid Clinical Holds and Future ProspectsWe believe that many questions remain unanswered on MariTide (AMG 133). Valuation still the key issue with the stock, in our view; while our DCF is ~$200 (inclusive of some obesity), to explain the current trading levels, investors appear to be relying on P/E based valuation methodologies.
BMO Capital
$362→$346
Buy
17.58%
Upside
Reiterated
01/29/25
Amgen (AMGN) PT Lowered to $346 at BMO CapitalBMO Capital analyst Evan David Seigerman lowered the price target on Amgen (NASDAQ: AMGN) to $346.00 (from $362.00) while maintaining a Outperform rating.
Goldman Sachs
$370
Buy
25.73%
Upside
Reiterated
01/15/25
Goldman Sachs reiterates Buy Rating on Amgen (AMGN)Goldman Sachs analyst Salveen Richter reiterated a Buy rating and $370.00 price target on Amgen (NASDAQ: AMGN)
Best Analysts Covering Amgen
Which Analyst Should I Follow If I Want to Buy AMGN and Sell After:
1 Month
xxx
Success Rate
15/29 ratings generated profit
Average Return
-0.50%
assigned a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 51.72% of your transactions generating a profit, with an average return of -0.50% per trade.
3 Months
xxx
Success Rate
22/35 ratings generated profit
Average Return
+4.78%
reiterated a xxx
rating 17 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.86% of your transactions generating a profit, with an average return of +4.78% per trade.
1 Year
Success Rate
25/35 ratings generated profit
Average Return
+12.08%
reiterated a buy rating 17 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +12.08% per trade.
2 Years
xxx
Success Rate
42/53 ratings generated profit
Average Return
+18.98%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 79.25% of your transactions generating a profit, with an average return of +18.98% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AMGN Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
0
0
0
0
0
Buy
40
43
38
31
22
Hold
27
34
26
18
11
Sell
2
1
1
2
3
Strong Sell
0
0
0
0
0
total
69
78
65
51
36
Each month's total comprises the sum of three months' worth of ratings.
AMGN Financial Forecast
AMGN Stock Forecast FAQ
What is AMGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Amgen’s 12-month average price target is $328.75.
What is AMGN’s upside potential, based on the analysts’ average price target?
Amgen has 11.72% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AMGN a Buy, Sell or Hold?
Amgen has a consensus rating of Moderate Buy which is based on 11 buy ratings, 7 hold ratings and 1 sell ratings.
What is Amgen’s price target?
The average price target for Amgen is $328.75. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $389.00 ,the lowest forecast is $275.00. The average price target represents 11.72% Increase from the current price of $294.27.
The highest analyst price target is $389.00 ,the lowest forecast is $275.00. The average price target represents 11.72% Increase from the current price of $294.27.
What do analysts say about Amgen?
Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of AMGN?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.